Keywords: raloxifene, data, lives, up, expectations, eli, lilly

Raloxifene Data Lives Up To Expectations

Article | 12 June 1997

Print This

Eli Lilly has reported pivotal Phase III data from a trial of itsselective estrogen receptor modulator raloxifene, which indicate that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in